Revised forecast
Fiscal year ending May 2026 · Full yearPrevious forecast published 14 April 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Net sales exceeded the previous forecast due to the earlier delivery of certain products and other factors, and operating income and ordinary income also exceeded the forecast as a result of the increase in net sales. However, net income fell below the previous forecast due to the recognition of an extraordinary loss related to an impairment loss arising from a review of the pharmaceutical synthesis business plan.
¥398 million impairment loss on fixed assets associated with the pharmaceutical synthesis business
| Item | Details |
|---|---|
| Net Sales | ¥7,700 million → ¥7,840 million（+1.8%） |
| Operating profit | ¥700 million → ¥742 million（+6.0%） |
| Ordinary income | ¥660 million → ¥707 million（+7.1%） |
| Profit attributable to owners of the parent | ¥470 million → ¥163 million（-65.3%） |
| Net income per share | 117.02 yen and sen → 40.58 yen and sen |
| Fiscal Period Covered | Fiscal year ending May 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 April 2026 |
| Previous-period results | Full year ended May 2025: net sales of ¥6,653 million, operating income of ¥432 million, ordinary income of ¥430 million, net income of ¥241 million, and net income per share of ¥60.42 |
| Reason for the revision | Net sales exceeded the previous forecast due to the earlier delivery of certain products and other factors, and operating income and ordinary income also exceeded the forecast as a result of the increase in net sales. However, net income fell below the previous forecast due to the recognition of an extraordinary loss related to an impairment loss arising from a review of the pharmaceutical synthesis business plan. |
| Details and amount of extraordinary loss | ¥398 million impairment loss on fixed assets associated with the pharmaceutical synthesis business |
| Dividend forecast revision | A year-end dividend of ¥16 per share is scheduled to be paid, as announced on 14 April 2026 |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales exceeded the previous forecast due to the earlier delivery of certain products and other factors, while operating income and ordinary income also increased. However, an impairment loss of ¥398 million on fixed assets associated with a review of the pharmaceutical synthesis business plan was recognized as an extraordinary loss, causing net income to fall below the previous forecast.